These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 23041621)
1. Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells. Qiu M; Peng Q; Jiang I; Carroll C; Han G; Rymer I; Lippincott J; Zachwieja J; Gajiwala K; Kraynov E; Thibault S; Stone D; Gao Y; Sofia S; Gallo J; Li G; Yang J; Li K; Wei P Cancer Lett; 2013 Jan; 328(2):261-70. PubMed ID: 23041621 [TBL] [Abstract][Full Text] [Related]
2. Coordinate hyperactivation of Notch1 and Ras/MAPK pathways correlates with poor patient survival: novel therapeutic strategy for aggressive breast cancers. Mittal S; Sharma A; Balaji SA; Gowda MC; Dighe RR; Kumar RV; Rangarajan A Mol Cancer Ther; 2014 Dec; 13(12):3198-3209. PubMed ID: 25253780 [TBL] [Abstract][Full Text] [Related]
3. MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth. Xu Z; Wang Z; Jia X; Wang L; Chen Z; Wang S; Wang M; Zhang J; Wu M Cancer Lett; 2016 Mar; 372(1):118-27. PubMed ID: 26739060 [TBL] [Abstract][Full Text] [Related]
4. HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer. So JY; Wahler J; Das Gupta S; Salerno DM; Maehr H; Uskokovic M; Suh N J Steroid Biochem Mol Biol; 2015 Apr; 148():111-21. PubMed ID: 25541438 [TBL] [Abstract][Full Text] [Related]
5. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2 Ly S; Anand V; El-Dana F; Nguyen K; Cai Y; Cai S; Piwnica-Worms H; Tripathy D; Sahin AA; Andreeff M; Battula VL J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722905 [TBL] [Abstract][Full Text] [Related]
6. O-Acetyl-GD2 as a Therapeutic Target for Breast Cancer Stem Cells. Cheng JY; Hung JT; Lin J; Lo FY; Huang JR; Chiou SP; Wang YH; Lin RJ; Wu JC; Yu J; Yu AL Front Immunol; 2021; 12():791551. PubMed ID: 35046949 [TBL] [Abstract][Full Text] [Related]
8. ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel. Mao J; Song B; Shi Y; Wang B; Fan S; Yu X; Tang J; Li L Int J Biochem Cell Biol; 2013 Jun; 45(6):1064-73. PubMed ID: 23500524 [TBL] [Abstract][Full Text] [Related]
9. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells. Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410 [TBL] [Abstract][Full Text] [Related]
10. NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell. Zhao ZL; Zhang L; Huang CF; Ma SR; Bu LL; Liu JF; Yu GT; Liu B; Gutkind JS; Kulkarni AB; Zhang WF; Sun ZJ Sci Rep; 2016 Apr; 6():24704. PubMed ID: 27108536 [TBL] [Abstract][Full Text] [Related]
14. Pien Tze Huang inhibits the proliferation, and induces the apoptosis and differentiation of colorectal cancer stem cells via suppression of the Notch1 pathway. Qi F; Wei L; Shen A; Chen Y; Lin J; Chu J; Cai Q; Pan J; Peng J Oncol Rep; 2016 Jan; 35(1):511-7. PubMed ID: 26530025 [TBL] [Abstract][Full Text] [Related]
15. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer. Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583 [TBL] [Abstract][Full Text] [Related]
16. Autophagy suppresses self-renewal ability and tumorigenicity of glioma-initiating cells and promotes Notch1 degradation. Tao Z; Li T; Ma H; Yang Y; Zhang C; Hai L; Liu P; Yuan F; Li J; Yi L; Tong L; Wang Y; Xie Y; Ming H; Yu S; Yang X Cell Death Dis; 2018 Oct; 9(11):1063. PubMed ID: 30337536 [TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer. Valcourt DM; Dang MN; Scully MA; Day ES ACS Nano; 2020 Mar; 14(3):3378-3388. PubMed ID: 32083466 [TBL] [Abstract][Full Text] [Related]
18. Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability. Chao MW; Chu PC; Chuang HC; Shen FH; Chou CC; Hsu EC; Himmel LE; Huang HL; Tu HJ; Kulp SK; Teng CM; Chen CS Oncotarget; 2016 Jan; 7(2):1796-807. PubMed ID: 26625202 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological Disruption of the Notch1 Transcriptional Complex Inhibits Tumor Growth by Selectively Targeting Cancer Stem Cells. Alvarez-Trotta A; Guerrant W; Astudillo L; Lahiry M; Diluvio G; Shersher E; Kaneku H; Robbins DJ; Orton D; Capobianco AJ Cancer Res; 2021 Jun; 81(12):3347-3357. PubMed ID: 33820800 [TBL] [Abstract][Full Text] [Related]
20. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin. Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]